{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=117", "query": { "intervention": "serum sample", "page": 117 }, "page_size": 10 }, "pagination": { "page": 117, "page_size": 10, "total_count": 8384, "total_pages": 839, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=118&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=116&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T16:45:59.788Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05084859", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-resistant Prostate Cancer", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "SM08502", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biosplice Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-11-03", "completion_date": "2022-10-20", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 16, "location_summary": "Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05084859" }, { "nct_id": "NCT03530696", "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Cancer", "Breast Cancer Stage", "Recurrent Breast Cancer", "Metastatic Breast Cancer", "HER2 Positive Breast Carcinoma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-12-06", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 16, "location_summary": "Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530696" }, { "nct_id": "NCT00081861", "title": "Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2004-03", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2012-04-05", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081861" }, { "nct_id": "NCT01321541", "title": "Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "de Novo DLBCL", "DLBCL Transformed From Indolent Lymphoma", "Follicular Grade 3 Lymphoma" ], "interventions": [ { "name": "Pixantrone + Rituximab", "type": "DRUG" }, { "name": "Gemcitabine + Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2011-04-20", "completion_date": "2018-09-14", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 51, "location_summary": "Tucson, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321541" }, { "nct_id": "NCT06824467", "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "H1 receptor antagonist", "type": "DRUG" }, { "name": "H2 receptor antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid mouthwash (dexamethasone or equivalent)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 770, "start_date": "2025-04-09", "completion_date": "2032-11-09", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Duarte, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06824467" }, { "nct_id": "NCT00066469", "title": "Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 55, "start_date": "2004-04", "completion_date": "2013-12-31", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066469" }, { "nct_id": "NCT00588822", "title": "Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precancerous Condition" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "21 Years to 90 Years" }, "enrollment_count": 21, "start_date": "2005-01", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2014-05-06", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588822" }, { "nct_id": "NCT00785629", "title": "A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Calcium acetate", "type": "DRUG" }, { "name": "Lanthanum Carbonate", "type": "DRUG" }, { "name": "Sevelamer Carbonate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Denver Nephrologists, P.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2009-02", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-10-30", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00785629" }, { "nct_id": "NCT00312845", "title": "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bortezomib + Rituximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 676, "start_date": "2006-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-06-25", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 41, "location_summary": "Opelika, Alabama • Alhambra, California • Bakersfield, California + 36 more", "locations": [ { "city": "Opelika", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00312845" }, { "nct_id": "NCT01371695", "title": "Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervical Cancer", "Cervical Intraepithelial Neoplasia II", "Cervical Intraepithelial Neoplasia III" ], "interventions": [], "intervention_types": [], "sponsor": "Onconix, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2011-05", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2011-06-13", "last_synced_at": "2026-11-11T16:45:59.788Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01371695" } ] }